FJX1 and nasopharyngeal carcinoma: Notwithstanding, elevated levels of FJX1 in NPCs and other cancers, and combined with the minimal expression in normal human vital organs suggested that this tumor antigen may have value for developing a cancer vaccine that offered benefit as well as fewer side effects to NPC patients.